Guggenheim raised the firm’s price target on Johnson & Johnson to $266 from $244 and keeps a Buy rating on the shares. The firm is updating its model following the company’s Q1 earnings this week and a detailed analysis on the Icotyde opportunity following its approval in plaque psoriasis last month. The firm is raising its Icotyde unadjusted peak revenue estimate to $14.9B from about $10B, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’
- Johnson & Johnson’s Stelara gets FDA approval for added indication
- Trump names Erica Schwartz CDC Director
- Best ETFs to Invest In, According to AI Analyst, 4/16/2026
- Trump Trade: White House launches space nuclear initiative